A trans-dominant mutational strategy was used to down-regulate
trypanothione reductase (TR) activity levels in Leishmania donovani, the causative agent of
visceral leishmaniasis in humans. TR, regarded as an ideal
drug target against trypanosomatid
infections, is a homodimeric
flavoprotein oxidoreductase unique to these organisms that plays a central role in the enzymatic regeneration of the
thiol pool. Extrachromosomal, heterologous expression of a trans-dominant mutant version of the Trypanosoma cruzi
enzyme in L. donovani resulted in the formation of inactive cross-species heterodimers and in a dramatic decrease of endogenous TR activity levels. Recombinant cells depleted of up to 85% of TR activity were significantly impaired in their ability to regenerate dihydrotrypanothione from
trypanothione disulfide following oxidation with
diamide. Nonetheless trans-dominant mutant recombinants were still capable of maintaining a reduced intracellular environment during cell growth in culture and were able to metabolize
hydrogen peroxide at wild-type rates in vitro. Importantly, however, cells expressing the trans-dominant mutant
enzyme displayed a decreased ability to survive inside activated macrophages in a murine model of
Leishmania infection. The apparent inability of Leishmania to modulate the expression of active TR homodimers in response to the expression of trans-dominant
mutant protein suggests that specific inhibitors of this
enzyme should be useful anti-leishmanial agents.